HC Wainwright Issues Pessimistic Outlook for CGEM Earnings

Key Points

• HC Wainwright lowered its Q3 2026 EPS estimate for Cullinan Therapeutics to a loss of $0.90 per share from $0.87, while projecting a $3.53-per-share loss for full-year 2026.
• Despite the more pessimistic earnings outlook, HC Wainwright maintained its Buy rating and $30 price target. Analysts overall rate CGEM “Moderate Buy,” with an average target of $32.14.
• Cullinan reported a Q2 loss of $0.81 per share, slightly worse than the $0.80 consensus estimate, while shares recently rose 7.4% to about $19.63. Institutional investors own a substantial 86.31% of the company.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Research analysts at HC Wainwright lowered their Q3 2026 EPS estimates for Cullinan Therapeutics in a report released on Monday, August 10th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.90) per share for the quarter, down from their previous estimate of ($0.87). HC Wainwright has a "Buy" rating and a $30.00 price objective on the stock. The consensus estimate for Cullinan Therapeutics' current full-year earnings is ($3.01) per share. HC Wainwright also issued estimates for Cullinan Therapeutics' Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($3.53) EPS, Q1 2027 earnings at ($0.77) EPS, Q2 2027 earnings at ($0.78) EPS, Q3 2027 earnings at ($0.80) EPS, Q4 2027 earnings at ($0.82) EPS and FY2027 earnings at ($3.17) EPS.

Several other research firms also recently commented on CGEM. Wall Street Zen downgraded Cullinan Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 1st. Wedbush reissued an "outperform" rating and issued a $37.00 target price on shares of Cullinan Therapeutics in a research report on Thursday, June 11th. Weiss Ratings restated a "sell (d-)" rating on shares of Cullinan Therapeutics in a research note on Wednesday, July 8th. Finally, BTIG Research upped their price target on Cullinan Therapeutics from $38.00 to $39.00 and gave the company a "buy" rating in a research report on Wednesday, July 29th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $32.14.

Cullinan Therapeutics Stock Up 7.4%

Shares of CGEM stock opened at $19.63 on Wednesday. The firm has a market cap of $1.26 billion, a P/E ratio of -6.33 and a beta of 0.01. The company has a 50 day moving average of $16.72 and a 200-day moving average of $14.94. Cullinan Therapeutics has a 12-month low of $5.68 and a 12-month high of $19.82.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.01).

Institutional Investors Weigh In On Cullinan Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of Cullinan Therapeutics in the second quarter worth $95,289,000. Affinity Asset Advisors LLC raised its stake in shares of Cullinan Therapeutics by 632.4% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,932,106 shares of the company's stock valued at $19,997,000 after purchasing an additional 1,668,289 shares during the period. Blue Owl Capital Holdings LP bought a new stake in shares of Cullinan Therapeutics during the 2nd quarter valued at $28,039,000. Lynx1 Capital Management LP lifted its holdings in Cullinan Therapeutics by 31.0% during the 3rd quarter. Lynx1 Capital Management LP now owns 5,766,090 shares of the company's stock worth $34,193,000 after purchasing an additional 1,365,248 shares in the last quarter. Finally, Boothbay Fund Management LLC purchased a new stake in Cullinan Therapeutics during the 4th quarter worth about $12,803,000. Institutional investors own 86.31% of the company's stock.

Insider Activity

In other news, insider Jennifer Michaelson sold 8,000 shares of the business's stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $17.82, for a total value of $142,560.00. Following the sale, the insider owned 162,844 shares of the company's stock, valued at $2,901,880.08. The trade was a 4.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 8.60% of the stock is currently owned by company insiders.

Key Stories Impacting Cullinan Therapeutics

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and maintained a $30 price target, implying substantial upside from the stock’s recent level near $19.63. The bullish target appears to be supporting investor sentiment, particularly as the shares trade close to their 52-week high.
• Neutral Sentiment: HC Wainwright projects continued quarterly losses but expects estimated EPS of ($0.77), ($0.78), ($0.80) and ($0.82) for the first four quarters of 2027, respectively, resulting in a projected FY2027 loss of ($3.17) per share. These forecasts provide investors with a view of the company’s expected cash-burning phase but do not signal near-term profitability.
• Negative Sentiment: HC Wainwright lowered its Q3 2026 EPS estimate to ($0.90) from ($0.87), Q4 2026 to ($0.93) from ($0.90), and FY2026 to ($3.53) from ($3.42). The revisions indicate somewhat higher expected losses and could limit gains despite the favorable rating and price target.
• Neutral Sentiment: Reported short interest was listed at zero shares, unchanged from the prior period, with a zero-day days-to-cover ratio. Because the figures appear incomplete or anomalous, they offer little actionable information about trading pressure.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source